DFFA抗体—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Flow cytometric analysis of Hela cells using DFFA mouse mAb (green) and negative control (red).    

  
  

The DFFA (DNA Fragmentation Factor Subunit Alpha) antibody is a crucial tool for studying apoptosis, a programmed cell death process essential for tissue homeostasis and disease regulation. DFFA, also known as DREP-1. forms a heterodimer with DFFB (DFF45/DFF40) to act as a chaperone and inhibitor of the caspase-activated DNase (CAD). During apoptosis, caspases cleave DFFA, releasing DFFB to trigger DNA fragmentation, a hallmark of apoptotic cell death. This cleavage disrupts the DFFA-DFFB complex, enabling DFFB to translocate to the nucleus and degrade chromosomal DNA into nucleosomal fragments, ensuring irreversible cell demise.

Antibodies targeting DFFA are widely used in biomedical research to detect endogenous protein levels, assess cleavage events, and investigate apoptosis dysregulation in cancer, neurodegenerative diseases, and developmental disorders. They enable techniques like Western blotting, immunofluorescence, and immunohistochemistry to visualize DFFA expression, localization, and caspase-mediated processing in cells or tissues. Commercial DFFA antibodies are typically raised against specific epitopes (e.g., human DFFA N-terminal residues) and validated for specificity across species (human, mouse, rat). Researchers rely on these antibodies to explore therapeutic strategies targeting apoptotic pathways or to diagnose diseases linked to defective cell death mechanisms. Proper controls (e.g., knockout validation) are critical to ensure antibody reliability in experimental settings.